Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?:
Abstract
887667 TAM0010.1177/1758835919887667Therapeutic Advances in Medical OncologyM Glas and S Kebir letter20192019 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Regorafenib in glioblastoma recurrence: 2019, Vol. 11: 1 –2 https://doi.org/10.1177/1758835919887667 DOI: 10.1177/ https://doi.org/10.1177/1758835919887667 how to deal with conflicting ‘real-life’ © The Author(s), 2019. Article reuse guidelines: experiences? sagepub.com/journals- permissions Martin Glas and Sied Kebir Correspondence to: To date, treatment options for glioblastoma recur- us to find an unusually high incidence of Martin Glas rence are scarce. Based on efficacy data from ran- Common Toxicity Criteria (CTC) grade 3 Division of Clinical Neurooncology, domized clinical trials, the nitrosourea compound adverse events to regorafenib in all but one Department of Neurology, CCNU (lomustine) is considered standard treat- patient. Among the most debilitating adverse University Hospital Essen, University Duisburg- ment after temozolomide failure. Treatment with events was a case of hand-foot-syndrome that Essen, Hufelandstr. 55, lomustine in recurrent glioblastoma yields did not respond to topical dermatological treat- 45147 Essen, Nordrhein- Westfalen, Germany median overall survival (mOS) ranging from 8.6– ment, and eventually led to the requirement for DKFZ-Division 9.8 months and median progression-free survival management with opioid analgesics to alleviate Translational 1–3 (mPFS) from 1.5–2.7 months. In a